IP Library Granted Patent US 7,459,085
Granted Patent B2
US 7,459,085 · App. 10/531,568 · Granted Dec 2, 2008

Microporous hydrophilic membrane

Assignee: Asahi Kasei Medical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,085
App. No.
10/531,568
Granted
Dec 2, 2008
Kind
B2
Abstract

A hydrophilic microporous membrane comprising a thermoplastic resin, having been subjected to hydrophilizing treatment and having a maximum pore size of 0 to 100 nm, wherein when 3 wt % bovine immunoglobulin having a monomer ratio of 80 wt % or more is filtered at a constant pressure of 0.3 MPa, an average permeation rate (liter/m 2 /h) for 5 minutes from the start of filtration (briefly referred to as globulin permeation rate A) satisfies the following formula (1) and an average permeation rate (liter/m 2 /h) for 5 minutes from the time point of 55 minutes after the start of filtration (briefly referred to as globulin permeation rate B) satisfies the following formula (2): Globulin permeation rate A >0.0015 ×maximum pore size (nm) 2.75   (1) Globulin permeation rate B /globulin permeation rate A >0.2 .   (2)

Claims (22)

1. A hydrophilic microporous membrane comprising a thermoplastic resin, having been contacted with a hydrophilic vinyl monomer having one vinyl group after generation of radicals by irradiation with ionizing radiation in order to be subjected to hydrophilizing treatment by a graft polymerization reaction, and having a maximum pore size of 10 to 100 nm,

wherein said hydrophilic microporous membrane has a coarse structure layer with a higher open pore ratio and a fine structure layer with a lower open pore ratio which are formed in one piece, wherein said coarse structure layer exists on at least one side of the membrane surface and has a thickness of 2 μm or more and a thickness of said fine structure layer is 50% or more of the whole membrane thickness,

wherein when 3 wt % bovine immunoglobulin having a monomer ratio of 80 wt % or more is filtered at a constant pressure of 0.3 MPa, an average globulin permeation rate A (liter/m 2 /h) for 5 minutes from the start of filtration satisfies the following formula (1) and an average globulin permeation rate B (liter/m 2 /h) for 5 minutes from the time point of 55 minutes after the start of filtration satisfies the following formula (2):

Globulin permeation rate A>0.0015 maximum pore size (nm) 2.75   (1)

Globulin permeation rate B /globulin permeation rate A >0.2  (2).

2. The hydrophilic microporous membrane according to claim 1 having a maximum pore size of 10 to 70 nm.

3. The hydrophilic microporous membrane according to claim 2 having a receding contact angle of water of 0 to 20 degrees.

4. The hydrophilic microporous membrane according to claim 1 having a maximum pore size of 10 to 36 nm.

5. The hydrophilic microporous membrane according to claim 4 having a receding contact angle of water of 0 to 20 degrees.

6. The hydrophilic microporous membrane according to claim 4 , wherein an accumulated permeation volume in three hours after the start of filtration is 50 liter/m 2 or more when 3 wt % bovine immunoglobulin having a monomer ratio of 80 wt % or more is filtered at a constant pressure of 0.3 MPa.

7. The hydrophilic microporous membrane according to claim 1 having a receding contact angle of water of 0 to 20 degrees.

8. The hydrophilic microporous membrane according to claim 1 , wherein a logarithmic reduction value of porcine parvovirus at the time point by which 55 liter/m 2 has been permeated from the start of filtration is 3 or more.

9. The hydrophilic microporous membrane according to claim 1 , wherein both of a logarithmic reduction value of porcine parvovirus at the time point by which 5 liter/m 2 has been permeated from the start of filtration and a logarithmic reduction value of porcine parvovirus at the time point by which further 5 liter/m 2 has been permeated after 50 liter/m 2 is permeated are 3 or more.

10. The hydrophilic microporous membrane according to claim 9 , wherein an accumulated permeation volume in three hours after the start of filtration is 50 liter/m 2 or more when 3 wt % bovine immunoglobulin having a monomer ratio of 80 wt % or more is filtered at a constant pressure of 0.3 MPa.

11. The hydrophilic microporous membrane according to claim 1 , wherein an accumulated permeation volume in three hours after the start of filtration is 50 liter/m 2 or more when 3 wt % bovine immunoglobulin having a monomer ratio of 80 wt % or more is filtered at a constant pressure of 0.3 MPa.

12. The hydrophilic microporous membrane according to claim 1 , wherein the thickness of the coarse structure layer is 3 μm or more.

13. The hydrophilic microporous membrane according to claim 1 , wherein the thickness of the coarse structure layer is 5 μm or more.

14. The hydrophilic microporous membrane according to claim 1 , wherein the thermoplastic resin is polyvinylidene fluoride.

15. The hydrophilic microporous membrane according to claim 1 , wherein the hydrophilizing treatment is a graft polymerization reaction of a hydrophilic vinyl monomer having one vinyl group to the surface of the pores of the hydrophilic microporous membrane.

16. The hydrophilic microporous membrane according to claim 15 , wherein the hydrophilic vinyl monomer contains a hydroxyl group.

17. The hydrophilic microporous membrane according to claim 1 , wherein the adsorption amount per 1 g of the membrane is 3 mg or less when dead-end filtration at a constant pressure of 0.3 MPa is performed using a 0.01 wt % bovine immunoglobulin solution and a filtrate of 50 liter/m 2 from the start of filtration is collected.

18. A method for removing a virus from a liquid containing a physiologically active substance, comprising filtering the liquid through the hydrophilic microporous membrane according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2008
From: ASAHI KASEI PHARMA CORPORATION
To: ASAHI KASEI MEDICAL CO., LTD.
Reel/Frame 020498/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2005
From: KOGUMA, ICHIRO; NAGOYA, FUJIHARU
To: ASAHI KASEI PHARMA CORPORATION
Reel/Frame 017046/0156 →
Priority Claims (3)
JP 2002-304766 · Oct 18, 2002 · national
JP 2002-376767 · Dec 26, 2002 · national
JP 2003-023709 · Jan 31, 2003 · national
Continuity (1)
Related Publication 20060016748A1 · Jan 26, 2006